Monthly Archives: July 2022

Press release 1 July 2022

Research Collaboration with Kyoto University in Biomaterial-assisted

Regenerative Medicine using HGF

Kringle Pharma, Inc. (Head office located in Osaka, Japan; President & CEO, Kiichi Adachi; "KRINGLE"), a late clinical-stage biopharmaceutical company, today announces signing of collaborative research agreement with Kyoto University (Located in Kyoto, Japan) focused on applied research combining HGF with biomaterials to create novel regenerative medicine products.

Professor Yasuhiko Tabata, Laboratory of Biomaterials, Institute for Life and Medical Sciences, Kyoto University, is a renowned leading scientist in the field of regenerative medicine utilizing biomaterials. Professor Tabata and KRINGLE jointly initiate applied research on regenerative medicine based on the biomaterial technologies and KRINGLE's recombinant human HGF (development code: KP-100). The goal of this collaboration is to develop biomaterial-assisted regenerative medicine using HGF for the treatment of incurable diseases.

Regenerative medicine is a treatment method that promotes the functional regeneration of tissues and organs by administering cells and other materials prepared outside the body to the damaged tissues or organs. In recent years, research on stem cell transplantation therapy using iPS cells and other stem cells has been attracting attention. The importance of biomaterials in regenerative medicine has been recognized, and intensive research is being conducted not only on their function as a scaffold for transplanted cells, but also on the combined use of drug delivery systems (DDS) technology and drugs to efficiently reach target cells, improve stability in vivo, and control drug release.

HGF is an endogenous biological protein responsible for the regeneration and repair of tissues and organs. Previous studies revealed that HGF administration resulted in functional recovery in animal models for various diseases. KRINGLE has been developing KP-100 for incurable diseases such as acute spinal cord injury, ALS, vocal fold scar and acute kidney injury. Through this collaboration, KRINGLE aims to maximize the therapeutic potential of HGF, expanding target indications over the existing pipelines, eventually providing novel therapies for patients suffering from incurable diseases.

About Hepatocyte Growth Factor (HGF)

HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs including not only liver, but also kidneys, heart, lungs, nerve tissues and skin.

About Biomaterials

Biomaterials are materials that are used in the body by itself or in combination with biological components including cells, proteins, nucleic acids or bacteria. Biomaterial technologies (e.g., scaffold to promote the formation of biological tissues, DDS technology to enhance the biological activity of proteins and genes that have cell differentiation and proliferation effects, etc.) can be utilized to enhance the regenerative and repair

capabilities of biological tissues.

Source: Yasuhiko Tabata, "Regenerative medicine in terms of DDS technology - Regenerative therapy and regenerative research," (2015)

About Kringle Pharma, Inc. https://www.kringle-pharma.com/en/

Kringle Pharma is a late clinical-stage biopharmaceutical company established in December 2001 to develop novel biologics based on HGF. Currently, Kringle's clinical programs with recombinant human HGF are: 1) Phase 3 ongoing in acute spinal cord injury, 2) investigator-initiated Phase 2 ongoing in ALS, 3) Phase 2/3 in preparation in vocal fold scar, and 4) Phase 1a and 1b completed in acute kidney injury. Kringle's mission is to contribute to societal and global healthcare through the continued research, development and commercialization of HGF drug for patients suffering from incurable diseases.

For more information, please contact

Daichika Hayata

Director, Pharmaceutical Development

Kringle Pharma, Inc.

Read the rest here:
Kringle Pharma : Research Collaboration with Kyoto University in Biomaterial-assisted Regenerative Medicine using HGF - Marketscreener.com

St. Paul, M.N.

--News Direct--

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that it was awarded a grant from Regenerative Medicine Minnesota for a project titled "Development of a Peripheral Nerve Wrap Using Regenerative Engineering Tissue Tube".

The one-year, $100,000 grant will commence in June 2022 and utilize Vascudyne's TRUE Tissue technology that is unique and 100% natural. The TRUE Tissue allogeneic biomaterial is completely biological, non-immunogenic and regenerates by the host. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine soft tissue biomaterials made from synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response.

Chronic nerve compression is one of the most common peripheral nerve injuries with carpal tunnel syndrome being the most common type of nerve compression affecting 3-6% of the general population. Tissues isolated from the patient are used in surgery but have shortcomings such as donor site morbidity, limited availability, and risk of surgical complications.

"We are excited to expand our TRUE Tissue platform technology to other soft tissue applications such as nerve repair," said Rick Murphy, Vascudyne's Chief Operating Officer. "The exquisite regenerative properties of our 100% biological biomaterial combined with its non-immunogenic properties and off-the-shelf availability are a perfect fit for addressing the challenging nerve injury applications. Demonstrating these benefits in a preclinical nerve injury model will greatly advance the field of peripheral nerve injury and offer a promising alternative to current treatments that often lack complete and functional nerve repair."

Vascudyne has prioritized commercialization of its cardiovascular products and recently announced the first clinical results of its regenerative vascular conduit for hemodialysis access. "While we are initially focusing on cardiovascular applications for our TRUE Tissue technology, we continue research and development efforts in other soft tissue applications such as nerve injury repair," stated Dr. Zeeshan Syedain, Vascudyne's Chief Scientific Officer. "This grant from the Regenerative Medicine Minnesota will help accelerate our preclinical animal study timeline and demonstrate safety and efficacy of the TRUE Tissue technology as a peripheral nerve wrap."

Vascudyne licensed its proprietary TRUE Tissue technology developed by world renowned tissue engineering leader Robert Tranquillo, PhD, Distinguished McKnight University Professor, and his colleagues from the University of Minnesota in 2017.

TRUE Tissue products are not available for commercial sale.

About Vascudyne

Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE Tissue technology to develop TRUE to Nature biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/.

About TRUE Tissue Technology

TRUE Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft.

Forward Looking Statements

This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne's clinical development programs, reflect management's current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne's actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Vascudyne, Inc.

Sandy Williams, Marketing Director

+1 952-412-5975

swilliams@vascudyne.com

Vascudyne, Inc.

View source version on newsdirect.com: https://newsdirect.com/news/vascudyne-receives-biobusiness-award-from-regenerative-medicine-minnesota-for-treatment-of-nerve-injury-723124309

2022 News Direct Corp.

Read the original:
Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury - - Benzinga

Toronto, Ontario, Canada, June 30, 2022 (GLOBE NEWSWIRE) -- Creative Destruction Lab (CDL) is launching a new Advanced Therapies stream for pre-seed and seed-stage ventures at the forefront of biotech. To bring this program to life, CDL has partnered with CCRM, a leader in accelerating the development and commercialization of regenerative medicine-based technologies.

Advanced Therapies will be launched at four world-class CDL locations the University of British Columbia, the University of Oxford, the University of Toronto, and the University of Wisconsin-Madison creating an international network that will foster the next generation of biotech companies.

Health tech is fundamentally changing treatment strategies the targeting of general symptoms in broad populations is being replaced by highly targeted therapies, and potential cures, in more refined patient subgroups. This sea change is a result of advancements in both molecular techniques and the analysis of biological data. CDL alumni ventures are among those companies at the forefront.

Advanced Therapies is for founders leveraging cell and gene therapies, biologics, antibody-drug conjugates, and other biological products to innovate solutions to biological, medical, and health-care issues.

CDLs Advanced Therapeutics stream combines a proven model for success and a founder-friendly mindset with a core group of biotech mentors who know what it takes to bring these therapies to patients. Adding CCRMs capabilities and expertise is like rocket fuel to accelerate the trajectory of these cutting-edge companies, said Dawn Bell, a CDL Health mentor and Global Development Head, Strategic Partnerships at Novartis.

This new stream will bring together entrepreneurs, investors, and scientists with expertise building massively scalable companies. Selected participants will work with these mentors to sharpen objectives, prioritize time and resources, raise capital, and build networks with experts working on the frontiers of research.

The growing number of startup founders working in advanced therapies, including CDL alumni such as Notch Therapeutics, have proven that Advanced Therapies is a necessary addition to CDLs programming. CDL is partnering with CCRM for the launch of this new stream.

Health tech is rapidly evolving to better serve people around the world. CDL, in partnership with CCRM, is eager to support cutting-edge research and founders who are looking to advance therapeutics and innovate the healthcare landscape, said Sonia Sennik, Executive Director at CDL.

CCRM, a global public-private partnership located in Toronto, Canada, has a deep network of researchers, investors, leading companies, and entrepreneurs that have been supporting the establishment of early-stage companies for a decade.

I always envisioned that CDL and CCRM would join forces to enhance early-stage company creation and company scaling in the area of advanced therapies, said Michael May, President and CEO, CCRM.

CCRM has a unique global position in this space. And I believe CDL is developing a best-in-class process of its own so it just seemed like a perfect marriage of skills, interests, and track record to partner in one of the hottest areas in biotech.

In addition to harnessing the global networks of CDL and CCRM, Advanced Therapies will leverage the academic and scientific communities of four leading institutions in North America and Europe. Each brings its own deep expertise and standout network in the field:

Join a CDL Health webinar to learn more. Companies and founders interested in applying to the Advanced Therapies stream can contact health@creativedestructionlab.com for more information. Applications will be accepted online until August 31, 2022.

About Creative Destruction Lab

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. Founded in 2012 by Professor Ajay Agrawal at the University of Torontos Rotman School of Management, the program has expanded to 12 sites across six countries. Participating ventures have created $20 billion (CAD) in equity value.

About Centre for Commercialization of Regenerative Medicine

CCRM is a global, public-private partnership headquartered in Canada. It receives funding from the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding and infrastructure. CCRM is hosted at its Toronto site by the University of Toronto and is the commercialization partner of Medicine by Design. Visit us at ccrm.ca.

Originally posted here:
CDL's new global Advanced Therapies stream brings together industry leader CCRM, four top universities on two continents - GlobeNewswire

Wilmington, Delaware, United States: Additive manufacturing or 3D printing is witnessing innovations left, right and center. In various industries such as education, manufacturing, engineering, and medical, the use is extensive. It is pertinent to note here that it is the printing of biomaterials such as cells, components etc. in three dimension and that while it is a new area, it has made notable advancement in the past few years.

Read Report Overview - https://www.transparencymarketresearch.com/3d-bioprinting-market.html

It is important to note here that basis the kind of material, approach of bioprinting changes. It also changes according to cell types, cell growth factors, and other complexities relating to living tissues. This happens because there is a need for process to be sensitive to differences in these cells.

The domain of 3D bioprinting comes into play in a number of disciplines. Some of these include cell biology, physics, biomaterial sciences, and engineering. And, this process can also be use by experts in these fields and researchers so a wide variety of tissue can be developed. Designing and sizing of bones, vascular grafts, multi-layered skin, cartilaginous structure, tracheal splints, and cardiac tissue. As 3D bioprinting is used widely in this field, market for the same will chart significant growth.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11657

Thus, it does not come as a surprise that as per a comprehensive market report brought out by Transparency Market Research (TMR), the global 3D bioprinting market is on a high growth trajectory over the forecast period of 2017 and 2025. The repost carries incisive insights on market dynamics and unravels trends and drivers that are shaping the landscape of the market over the coming years. Besides, it gives a peek into regional growth potential share, and opportunities, etc.

3D Bioprinting Market Key Trends and Drivers

Demand or high throughput models of tissue, used extensively in drug research and discovery processes, is all set to propel growth in the global bioprinting market. And, since pharmaceutical and biotechnology market are coextensive with 3D bioprinting, development in the former leads to growth in the latter. Here, it is worth noting that advanced drug screening is also adding to the growth curve of the global 3D bioprinting market in a positive manner.

Get COVID-19 Analysis on 3D Bioprinting Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=11657

Additionally, extensive use in regenerative therapies which includes transplantation and generation will also underpin notable growth in the market. And, the advancements in regenerative medicine is also supporting this growth curve over the forecast period.

3D Bioprinting Market Key Players

The global 3D bioprinting market is fragmented and key players in the landscape include TeVido BioDevices, Rainbow Biosciences, 3D Systems, Inc., regenHU, EnvisionTEC GmbH, Stratasys Ltd., nScrypt, Inc., Regenovo Biotechnology Co., GeSiM, and Aspect Biosystems Ltd. These are profiled in the report and provide insight into strategies deployed by each to maintain a prominent hold over the global 3D bioprinting market.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=11657

3D Bioprinting Market Regional Analysis

The regional analysis of the report is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Europe and North America will account for a prominent share of the global bioprinting market. There is a high demand for 3D printing in advanced clinical applications in the region. It is important to talk here of the upscaling of research and development in biotechnology and pharmaceutical industry in a number of North American and European countries.

More Trending Reports by Transparency Market Research

Medical Waste Containers Market: https://www.transparencymarketresearch.com/medical-waste-containers-market.html

Pressure Relief Devices Market: https://www.transparencymarketresearch.com/pressure-relief-devices.html

Orthopedic Devices Market: https://www.transparencymarketresearch.com/orthopedic-devices-market.html

Dental Implants Market: https://www.transparencymarketresearch.com/dental-implants-market.html

Virus Purification Kits Market: https://www.transparencymarketresearch.com/virus-purification-kits-market.html

Hemoglobin A1c Testing Devices Market: https://www.transparencymarketresearch.com/hemoglobin-a1c-testing.html

Medical Image Analysis Software Market: https://www.transparencymarketresearch.com/medical-image-analysis-software-market.html

Extracorporeal Membrane Oxygenation Machine Market: https://www.transparencymarketresearch.com/extracorporeal-membrane-oxygenation-machine-market.html

About Us

Transparency Market Research is a global market research firm offering the latest market research reports and business consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See original here:
3D Bioprinting Market: Rise in Prevalence of Regenerative Therapies to Drive the Global Market - BioSpace

ByDanny Jacobs

Two faculty teams with members affiliated with the Johns Hopkins Whiting School of Engineering have received grants for their research through the Cohen Translational Engineering Fund.

The fund, made possible by a generous commitment from Sherry and Neil Cohen '83, serves as a catalyst for translating cutting-edge research into practice by providing faculty with critical early funding. The grant is designed to help researchers move their work out of the laboratory and toward commercializationthe process includes developing patents, obtaining materials and supplies, and building prototypes.

"We are pleased to continue helping Whiting School of Engineering faculty advance their cutting-edge research," says Neil Cohen, who is also the founder of venture capital firm Emerald Development Managers. "Previous grantees are already realizing promising developments in their work, and we look forward to seeing this year's grantees further strengthen the pipeline of innovation and entrepreneurship coming out of the Whiting School of Engineering and Johns Hopkins."

Grantees receive a maximum of $100,000 for a nine-month project. Since its inception eight years ago, the Cohen Fund has awarded more than $1.3 million for 28 projects. Among the past recipients are LifeSprout, a regenerative medicine company; Ready Robotics, creator of operating software for industrial automation; Galen Robotics, which is developing steady-hand surgical robots; and Vectech, which is developing a surveillance system of cloud-connected smart mosquito traps.

A panel of experienced researchers, engineers, startup entrepreneurs, and business executives reviewed presentations from the five faculty finalists for this year's award in March.

"This year's recipients reflect the wide breadth of research done at the Whiting School and the key role that many Whiting faculty members play in cross-school collaborations," says Brian Stansky, senior director of FastForward. "Once again, the generous funding provided by Sherry and Neil Cohen will help multiple faculty members meaningfully move their academic research toward commercialization. We look forward to working with both recipient teams over the course of these projects and beyond."

The grantees are detailed below.

Principal investigator: Mark Foster, associate professor, Department of Electrical and Computer Engineering

The pitch: Monitoring 3D laser printing in real time to save manufacturers time and money

Laser powder bed fusion, or LPBF, is a 3D-printing process that uses high-powered lasers to rapidly melt and solidify metal powder into 3D objects such as heat sinks (which move heat away from a hot device) and jet fuel nozzles. The process, known as additive manufacturing, often leads to microscopic, random defects in the object, costing manufacturers time and money to replace parts.

Image caption: Mark Foster

Foster, working with Milad Alemohammad, a postdoctoral fellow, and Steven Storck, a senior materials scientist at the Johns Hopkins University Applied Physics Laboratory, has created novel, high-speed spectroscopic sensors that can be integrated into LPBF printing machines and provide real-time data so operators can correct defective layers as the object is being made.

The team developed the sensor at the request of collaborators at JHU APL's additive manufacturing center. They have received $250,000 in seed funding sponsored by the Army Research Laboratory and enabled by the MEDE+ AI-M program at the Hopkins Extreme Materials Institute, and they have taken part in the National Science Foundation's I-Corps program through Johns Hopkins Technology Ventures.

The team plans to use the funding to continue to refine its sensors as well as develop a user dashboard.

Principal investigators: Danielle Gottlieb Sen, director of pediatric cardiac surgery at Johns Hopkins Medicine and Youseph Yazdi, assistant professor of biomedical engineering and executive director of the Center for Bioengineering Innovation and Design

The pitch: Detecting a potentially deadly disease in infants and premature babies before symptoms appear

Image caption: Danielle Gottlieb Sen

Necrotizing enterocolitis, or NEC, is an often-fatal intestinal disease that disproportionately affects infants with congenital heart disease as well as premature babies. Treatment of NEC is most effective when started early, but currently, a diagnosis is confirmed only after symptoms appear, at which point substantial damage may already have occurred. Treatment can involve extended hospital stays or surgeries, and NEC can cause lifelong complications.

Image caption: Youseph Yazdi

Gottlieb Sen and Yazdi, working with Ellen Roche, on faculty at the Institute for Medical Engineering & Science at the Massachusetts Institute of Technology, are developing a noninvasive device that goes on a baby's belly to monitor intestinal ischemia, inadequate blood flow that is a known biomarker of the onset of NEC. The device, which will connect to bedside monitors, uses near-infrared spectroscopy, or NIRS, sensors to continuously record, store, and transmit data.

The team is building NIRS sensors that account for differences in pediatric patient size, and they are mapping pediatric intestine and vascular beds to ensure monitoring specificity. Their work could serve as a platform to develop accurate NIRS sensors for others tissues and diseases.

The team plans to use the funding to build the device as well as obtain results to start the process of receiving device approval from the U.S. Food and Drug Administration.

See the original post:
Meet the newest grantees of the Cohen Translational Engineering Fund - The Hub at Johns Hopkins

Patients struggling with weight loss can look no further than the Doctors Clinic, and specifically the practice of Gerald Parker, DO.

For patients who have tried dieting but failed to lose weight and keep it off, its time to try something different. At Doctors Clinic in Amarillo, Texas, Gerald Parker, DO has been helping patients of all ages lose weight for over 39 years with personalized medical weight loss programs. If youre ready to commit to your health and finally get rid of your extra pounds, contact Doctors Clinic or make an appointment online today.

What do medical weight loss programs include?

Doctors Clinic has a unique approach to weight loss. The providers dont rely on fads or gimmicks they help you change your relationship with food so you can follow a sensible, delicious, and sustainable diet and incorporate safe, moderate exercise into your daily routine.

Health assessment

Your doctor provides an exam and testing to identify how much weight you need to lose and whether you have any conditions that will affect your weight loss journey. They also track your blood pressure and glucose and cholesterol levels so you can see more improvements than just the number on the scale.

Meal planning

Your doctor helps you create a nutritious meal plan using real food that you buy at the grocery store. They can help you adjust your diet to get through plateaus or add variation if you need it. They also teach you about macros, nutrients, and other details to consider when choosing food.

Motivation

Making changes is challenging, but Doctors Clinic is in your corner every day. You have regular appointments to check your progress and adjust your program as necessary. You have small goals to keep you motivated as you work toward your ideal weight. Trust the medical weight loss program your doctor believes in your success.

Dr. Parker has been a guest speaker at national physician meetings including those for physicians specializing in weight loss. His nearly four decades of providing expert guidance and personalized care to patients put him at the forefront of medical professionals with the acumen to ensure every patient meets their goal.

Doctors Clinic offers cutting-edge regenerative and integrative medicine therapies to address each patients individual needs. A holistic, patient-focused approach helps patients address issues ranging from allergies and pain to weight management, while also enhancing their overall health and well-being.

Doctors Clinic welcomes new patients who are ready to improve their quality of life with personalized care and work with a true wellness partner. Appointments are available by calling the practice or using the online scheduling tool.

About Doctors Clinic:

Doctors Clinic, in Amarillo, Texas, is a state-of-the-art practice providing comprehensive health services for adult patients and specializing in regenerative medicine. Gerald Parker, DO is an experienced and compassionate provider who is committed to helping patients look and feel their best. The practice is happy to help patients on their wellness journey, whether theyre looking to enhance their health or if they need support to recover from injuries or diseases quickly and safely.

Media ContactCompany Name: Doctors ClinicContact Person: Gerald ParkerEmail: Send EmailPhone: (806) 355-8263Country: United StatesWebsite: Doctorsclinicamarillo.com

View post:
Doctors Clinic welcomes new patients who are ready to improve their quality of life - Digital Journal